|Bid||1.8000 x 2200|
|Ask||1.8200 x 800|
|Day's Range||1.6600 - 1.8650|
|52 Week Range||0.7600 - 4.3400|
|Beta (5Y Monthly)||0.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 08, 2021 - Feb 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced today the appointment of Charles J. Fisher, Jr., M.D., as Chief Executive Officer, effective as of October 30, 2020. Dr. Fisher joined Aethlon as a member of Aethlon's Board of Directors and has served as Chairman of the Board since November 2017. Mr. Ed Broenniman replaced Dr. Fisher as the Chairman of the Board effective as of October 30, 2020. Dr. Fisher brings an impressive record of results in global, strategic and operational roles to Aethlon. Dr. Fisher succeeds Dr. Timothy Rodell, who will serve as a consultant to Aethlon during the transition.
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Aethlon Medical Inc. (NASDAQ:AEMD), a medical technology company engaged in developing products to diagnose and treat diseases in oncology and viral diseases that are life and organ threatening and not addressed with already approved treatments, reported 2Q FY 2021 results last night and provided a business update. The company’s lead
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2020 and provided an update on recent developments.